Skip to content

Genetic Analysis of Birt Hogg-Dube Syndrome and Characterization of Predisposition to Kidney Cancer

Birt-Hogg-Dub(SqrRoot)(Copyright) Syndrome: Characterization of the FLCN Disease Gene and Predisposition to Renal Cancer, Cutaneous Fibrofolliculoma and Pulmonary Cysts

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00033137
Enrollment
950
Registered
2002-04-08
Start date
2002-05-13
Completion date
Unknown
Last updated
2026-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

FLCN Protein, Human, Kidney Cancer, Kidney Neoplasms, Pneumothorax

Keywords

Pneumothorax, Kidney, Fibrofolliculoma, BHD, Neoplasms, Natural History

Brief summary

This study will investigate the genetic cause of Birt Hogg-Dube (BHD) syndrome and the relationship of this disorder to kidney cancer. BHD is a rare inherited condition characterized by papules, or bumps-benign tumors involving hair follicles-on the head and neck. People with BHD are at increased risk of developing kidney cancer. Scientists have identified the chromosome (strand of genetic material in the cell nucleus) that contains the BHD gene and the region of the gene on the chromosome. This study will try to learn more about: * The characteristics and type of kidney tumors associated with BHD * The risk of kidney cancer in people with BHD * Whether more than one gene causes BHD * The genetic mutations (changes) responsible for BHD Individuals with known or suspected Birt Hogg-Dube syndrome, and their family members, may be eligible for this study. Candidates will be screened with a family history and review of medical records, including pathology reports for tumors, and films of computed tomography (CT) and magnetic resonance imaging (MRI) scans. Participants may undergo various tests and procedures, including the following: * Physical examination * Review of personal and family history with a cancer doctor, cancer nurses, kidney surgeon, and genetic counselor * Chest and other x-rays * Ultrasound (imaging study using sound waves) * MRI (imaging study using radiowaves and a magnetic field) * CT scans of the chest and abdomen (imaging studies using radiation) * Blood tests for blood chemistries and genetic testing * Skin evaluation, including a skin biopsy (surgical removal of a small skin tissue sample for microscopic evaluation) * Cheek swab or mouthwash to collect cells for genetic analysis * Lung function studies * Medical photography of skin lesions These tests will be done on an outpatient basis in either one day or over 3 to 4 days. When the studies are complete, participants will receive counseling about the findings and recommendations. Individuals with kidney lesions may be asked to return periodically, such as every 3 to 36 months, based on their individual condition, to document the rate of progression of the lesions. ...

Detailed description

Background: * Birt-Hogg-Dube (BHD) is a rare, autosomal dominantly inherited disorder which confers susceptibility to develop multifocal, bilateral renal cancer, spontaneous pneumothorax and fibrofolliculomas. * BHD is caused by mutations in the FLCN gene located on Chromosome17p11.2 * Defining the genetic and biochemical pathways leading to renal tumorigenesis in BHD may lead to the development of new molecularly targeted drugs. Objectives: * To define the types and characteristics (including patterns of growth) of renal cancer associated with BHD * To determine the risk of renal cancer, lung cysts and fibrofolliculomas in individuals with BHD * To define the natural history of BHD related renal tumors * To determine if other genes contribute to BHD * Identify genotype/phenotype correlations Eligibility: -Individuals that meet one or more of the following criteria: --Suspected or known to have phenotype or genotype suggestive of Birt-Hogg-Dube (BHD), such as: * Individuals with histologically confirmed fibrofolliculomas * Individuals with clinical evidence of multiple skin papules consistent with fibrofolliculomas, and/or a family history of spontaneous pneumothorax or kidney cancer * Individuals with a known germline FLCN mutation or --Renal tumor histology consistent with BHD, including, but not limited to those suggestive of chromophobe, hybrid oncocytic neoplasm or oncocytoma or --Are a relative (related by blood) of an individual with a confirmed or suspected diagnosis of BHD Design: * These rare families will be recruited to genetically confirm diagnosis, determine size and location of renal tumors, size at presentation, growth rate and metastatic potential of renal tumors. * Genetic testing will be offered to gain appreciation of the effect of mutations the BHD gene and to assess the relative activity of various germline and somatic mutations. * We will determine if there is a relationship between mutation and disease manifestations and phenotype.

Interventions

None listed

Sponsors

National Cancer Institute (NCI)
Lead SponsorNIH

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
2 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* INCLUSION CRITERIA: Individuals that meet one or more of the following criteria: -Suspected or known to have phenotype or genotype suggestive of Birt-Hogg-Dube (BHD), such as: --Individuals with at least one histologically confirmed fibrofolliculomas; or --Individuals with clinical evidence of multiple skin papules (without fibrofolliculoma biopsy confirmation) and a personal or family history of spontaneous pneumothorax/or kidney cancer; or --Individuals with spontaneous pneumothorax and skin papules or kidney cancer and a positive family history of spontaneous pneumothorax, skin papules or kidney cancer; or --Individuals with a known germline FLCN gene mutation OR -Renal tumor histology consistent with BHD, including, but not limited to those suggestive of chromophobe, hybrid oncocytic neoplasm or oncocytoma. OR * Are a relative (related by blood) of an individual with a confirmed or suspected diagnosis of BHD. -Participants must be \>= 2 years of age. * For children less than 18 years of age, parental permission or legal guardian consent will be obtained.

Exclusion criteria

None.

Design outcomes

Primary

MeasureTime frameDescription
Identify genotype / phenotype correlations.on-goingCollection of blood, saliva, tissue \& urine for Identification of the Disease Gene, and Characterization of the disposition to Renal Cancer
Determine risk of renal cancer, lung cysts and fibrofollicullomas in patients with BHD.on-goingCollection of blood, saliva, tissue \& urine for Identification of the Disease Gene, and Characterization of the disposition to Renal Cancer
Determine if other genes contribute to BHD.on-goingCollection of blood, saliva, tissue \& urine for Identification of the Disease Gene, and Characterization of the disposition to Renal Cancer
Define types and characteristics (including patterns of growth) of renal cancer associated with BHD.on-goingCollection of blood, saliva, tissue \& urine for Identification of the Disease Gene, and Characterization of the disposition to Renal Cancer
Define the natural history of BHD related renal tumors.on-goingCollection of blood, saliva, tissue \& urine for Identification of the Disease Gene, and Characterization of the disposition to Renal Cancer

Countries

United States

Contacts

CONTACTDeborah A Nielsen, R.N.
deborah.nielsen@nih.gov(240) 760-6247
CONTACTW. Marston Linehan, M.D.
linehanm@mail.nih.gov(240) 858-3700
PRINCIPAL_INVESTIGATORW. Marston Linehan, M.D.

National Cancer Institute (NCI)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 17, 2026